Figure 7. Plasma Ectosomal PKM2 Is a Promising Marker for HCC Diagnosis (A) Experimental scheme, liver images (scale bar, 1 cm), and liver section (scale bar, 2 mm) of the DEN/CCl4 HCC mouse model. (B and C) PKM2 levels in plasma ectosomes between vehicle (n = 8) and DEN/CCl4...
of 5000 ng/mL. You biopsy them, and they’re a mixed subtype with anFGFRmutation or fusion, and they respond nicely to targeted therapy. We’ve all seen this if we do this all day. I’m of the opinion that it’s fine to start therapy when you have a radiographic diagnosis. If th...
Collecting the cells after 36 h and analyzing them with the appropriate antibodies. c Huh7 cell infection with lentivirus expressing either an empty vector or USP37-Flag. Harvesting the cells and subjecting them to protein analysis using relevant antibodies. d Determining NRF2 RNA levels in Huh7...
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths worldwide1. The poor prognosis of HCC can be attributed to the fact that diagnosis is often made at a late stage in disease development2,3. Earlier detection of HCC is critical to reducing high HCC mortal...
FROC curve analysis of the predictive value of the AC099850.3 high and low expression groups in HBV-HCC diagnosis;GAnalysis of the differences in immune cell composition between AC099850.3 high and low expression groups, where the x-axis represents immune cell types and the y-axis represents the...
The criteria for HCC diagnosis using gadoxetic acid–enhanced MRI are broadly similar across Eastern guidelines (Table 1). A key differentiating factor between Eastern and West- ern guidelines is the timing of assessment after gadox- etic acid administration—i.e., whether assessing washout in ...
only <20% of HCC patients were resectable upon diagnosis4. Even after radical resection, the 5-year recurrence rate of HCC is up to 70%, posing a big challenge for the long-term survival of patients3,5,6. The pattern of recurrence is typically within the liver, which might originate fro...
Moreover, tumor recurrence is observed in 50 to 80% of patients at 5 years after treatment, with most relapses occurring within 2 years7. Therapeutic options in advanced unresectable HCC are limited to Sorafenib which is the only approved therapy confirmed to provide a limited increase in ...
1 After a decade of failures in phase III trials, the systemic treatment armamentarium for patients with unresectable/advanced HCC has significantly widened. Three multitargeted tyrosine kinase inhibitors (TKIs) – namely lenvatinib in the first line,2 regorafenib,3 and cabozantinib4 in sorafenib-...
Disease management depends on the tumor stage at the time of diagnosis and the overall condition of the liver. If possible, parts of the liver (partial hepatectomy) or the whole organ (liver resection) is removed by surgery. Especially patients with small or completely resectable tumors are qual...